BioNTech Faces Its Oncology Reckoning as ASCO Data Arrives with Analyst Backing

The oncology world has descended on Chicago this weekend, and for BioNTech, the stakes could hardly be higher. The company's shares rose 2.7% to $95.95 on Friday in U.S. trading, while the German listing settled at €82.35, as anticipation built ahead of the American Society of Clinical Oncology (ASCO) annual meeting. But the real test comes now: the Mainz-based biotech must prove that its sprawling cancer pipeline—spanning more than 25 ongoing Phase 2 and 3 trials, including 13 pivotal studies—can deliver the kind of data that turns scientific ambition into commercial reality.

Investors received an early vote of confidence. On May 27, UBS lifted BioNTech from "Neutral" to "Buy" and raised its price target from $117 to $135, citing growing conviction in the oncology pipeline's market potential. The upgrade arrived on the heels of a first-quarter earnings report that painted a starkly mixed picture: revenue of €118.1 million and a net loss of €531.9 million, driven largely by the continued decline of COVID-19 vaccine sales. For UBS, the pivot to cancer is not just a story—it is a necessity.

The company's ASCO presence is unusually broad. BioNTech is delivering two oral presentations and four posters, headlined by data on its bispecific antibody pumitamig in first-line non-small cell lung cancer. The interim analysis from the dose-optimization portion of the Phase 2/3 ROSETTA Lung-02 trial covers both squamous and non-squamous tumors across all PD-L1 expression levels, targeting a large and fiercely contested patient population. Those results are feeding directly into an ongoing pivotal Phase 3 study where pumitamig plus chemotherapy is going head-to-head against Merck's established frontline standard, Keytruda. This is not just another data point—it is a litmus test for whether BioNTech's platform can compete clinically with the market leaders.

Alongside pumitamig, the antibody-drug conjugate (ADC) gotistobart is drawing attention in platinum-resistant ovarian cancer. Phase 2 data suggest durable antitumor activity and a manageable safety profile, with clinically relevant overall survival. Gotistobart targets CTLA-4 and is designed to deplete regulatory T cells, making it a strategic fit for BioNTech's broader ambition to test combinations across multiple platforms, including its ADC pipeline. By year-end, the company expects 15 active Phase 3 studies, with seven late-stage oncology data packages due in 2026 and a planned U.S. filing for trastuzumab pamirtecan.

Should investors sell immediately? Or is it worth buying BioNTech?

Financially, BioNTech remains well-capitalized but under operational pressure. First-quarter revenue fell to $138.0 million (roughly €118.1 million at current rates) while the net loss widened to $622.3 million. Research and development spending hit $651.6 million, underscoring the cost of the oncology pivot. For the full year, management maintains its revenue guidance of $2.3 billion to $2.6 billion, backed by a liquidity cushion of $19.6 billion. The company has also announced a $1.0 billion share buyback program over twelve months, a signal of confidence even as it restructures.

That restructuring is substantial. BioNTech is exiting production sites in Idar-Oberstein, Marburg, Singapore, and CureVac locations, affecting roughly 1,860 positions. The cuts are expected to generate annual savings of about $584.9 million by 2029, freeing capital for the cancer push.

Analyst sentiment remains broadly constructive despite the stock's recent weakness. The consensus target among 17 analysts stands at $125.45, well above Friday's $95.95 close, though the range is wide: Canaccord Genuity cut its target from $171 to $158 but stays positive, while Leerink is more cautious at $94. On the technical side, the German share price sits 1.6% above its 50-day moving average of €81.06 but 4.5% below the 200-day line. The 52-week high of €101.90 is nearly 19% above current levels, and the RSI of 53.4 signals neutral territory. Resistance is pegged at $97.44 (Friday's high) with support at $93.44 (Thursday's close) and the May low of $87.53.

BioNTech at a turning point? This analysis reveals what investors need to know now.

The next few trading days will determine whether the pre-conference optimism was warranted. For BioNTech, the breadth of its oncology pipeline is no longer enough—the market is waiting for data that translates into a credible path to approval and revenue beyond COVID-19. ASCO is where that translation must begin.

Ad

BioNTech Stock: New Analysis - 30 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69448332 |